Literature DB >> 30506712

Prognostic evaluation of NANOG and OCT4 expression for posttransplantation hepatocellular carcinoma recurrence.

Wenjuan Cai1, Zhenglu Wang1,2, Chunfang Wei3, Meng Wu3, Weiping Zheng4, Haiming Zhang5, Chenghu Liu3, Lei Liu6,7.   

Abstract

Postoperative hepatocellular carcinoma (HCC) recurrence and metastasis throw great threaten to its overall survival (OS). This paper focus on exploring the prognostic significance of NANOG and OCT4 expression in HCC recurrence and OS after liver transplantation. Eighty-six patients who meet University of California San Francisco (UCSF) criteria and underwent liver transplantation in Tianjin First Central Hospital between August 2010 and August 2013 were included. Expression of NANOG and OCT4 was determined by immunohistochemistry. The relationships between NANOG and OCT4 expression with tumor recurrence, tumor count, histology stage, lymph node metastasis (LNM) and microvascular invasion (MVI) were explored through the χ2 test and Cox regression analysis. We found that 19/26 and 20/24 patients with positive expression of NANOG and OCT4 relapsed. Combination of NANOG and OCT4 expression was indicated as valuable prognostic signature for HCC recurrence prediction (P < 0.0011). Besides, we identified other key factors with significant correlations with recurrence, such as LNM (P = 0.011) and MVI (P = 0.024). Strikingly, recurrence sites could significantly affect recurrence time (P = 0.0062) and patients with recurrence in transplanted liver have longer recurrence time. In conclusions, we analyzed the relationships between NANOG/OCT4 expression, clinicopathology features, HCC recurrence, and OS after liver transplantation for the first time. Combination of NANOG, OCT4, LNM, histopathological stage, and MVI may be predictor for HCC recurrence posttransplantation. Comprehensive of histopathological stage grade and LNM were considered as prognosis factor for OS after liver transplantation. This should be helpful for treatment method selection for HCC patients after liver transplantation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  NANOG; OCT4; hepatocellular carcinoma; liver transplantation; overall survival; recurrence

Year:  2018        PMID: 30506712     DOI: 10.1002/jcb.28128

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas.

Authors:  Changhwan Yoon; Jun Lu; Brendan C Yi; Kevin K Chang; M Celeste Simon; Sandra Ryeom; Sam S Yoon
Journal:  Oncogenesis       Date:  2021-01-19       Impact factor: 7.485

2.  Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma.

Authors:  Yongrong Lei; Xishu Wang; Heng Sun; Yuna Fu; Yichen Tian; Ludi Yang; Jianhua Wang; Feng Xia
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

3.  Big Data-Based Identification of Multi-Gene Prognostic Signatures in Liver Cancer.

Authors:  Meiliang Liu; Xia Liu; Shun Liu; Feifei Xiao; Erna Guo; Xiaoling Qin; Liuyu Wu; Qiuli Liang; Zerui Liang; Kehua Li; Di Zhang; Yu Yang; Xingxi Luo; Lei Lei; Jennifer Hui Juan Tan; Fuqiang Yin; Xiaoyun Zeng
Journal:  Front Oncol       Date:  2020-05-28       Impact factor: 6.244

Review 4.  Homeobox Genes and Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu; Shen-Nien Wang
Journal:  Cancers (Basel)       Date:  2019-05-03       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.